• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Aβ成像简史。

A brief history of Aβ imaging.

作者信息

Cohen Ann D, Villemagne Victor L

机构信息

Department of Psychiatry, The University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

出版信息

Alzheimers Dement. 2025 May;21(5):e70291. doi: 10.1002/alz.70291.

DOI:10.1002/alz.70291
PMID:40407091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12100503/
Abstract

β-Amyloid (Αβ) imaging revolutionized the in vivo assessment of Alzheimer's disease (AD) Αβ pathology and its changes over time, increasing our insights into Aβ deposition in the brain by providing highly accurate, reliable, and reproducible quantitative statements of regional and global Aβ burden in the brain, proving essential for the differential diagnosis, staging, and evaluation of disease-specific anti-Αβ therapeutic approaches. Longitudinal observations, coupled with different disease-specific biomarkers to assess potential downstream effects of Aβ, have confirmed that Αβ deposition in the brain starts decades before the onset of symptoms. Aβ imaging studies continue to refine our understanding of the role of Αβ deposition in AD, and its relation to other imaging and fluid biomarkers. HIGHLIGHTS: Αβ imaging revolutionized the in vivo assessment of Alzheimer's disease Αβ pathology. Αβ imaging has increased our insights into Aβ deposition in the brain by providing highly accurate, reliable, and reproducible quantitative statements of regional and global Αβ burden in the brain. Αβ imaging is essential for the differential diagnosis, staging, and evaluation of disease-specific anti-Αβ therapeutic approaches. Αβ imaging studies continue to refine our understanding of the role of Αβ deposition in Alzheimer's disease, and its relation to other imaging and fluid biomarkers.

摘要

β-淀粉样蛋白(Aβ)成像彻底改变了阿尔茨海默病(AD)Aβ病理的体内评估及其随时间的变化,通过提供大脑区域和整体Aβ负担的高度准确、可靠且可重复的定量数据,增加了我们对大脑中Aβ沉积的认识,这对疾病特异性抗Aβ治疗方法的鉴别诊断、分期和评估至关重要。纵向观察,结合不同的疾病特异性生物标志物来评估Aβ的潜在下游效应,证实大脑中的Aβ沉积在症状出现前数十年就已开始。Aβ成像研究不断完善我们对Aβ沉积在AD中的作用及其与其他成像和体液生物标志物关系的理解。

要点

Aβ成像彻底改变了阿尔茨海默病Aβ病理的体内评估。Aβ成像通过提供大脑区域和整体Aβ负担的高度准确、可靠且可重复的定量数据,增加了我们对大脑中Aβ沉积的认识。Aβ成像对疾病特异性抗Aβ治疗方法的鉴别诊断、分期和评估至关重要。Aβ成像研究不断完善我们对Aβ沉积在阿尔茨海默病中的作用及其与其他成像和体液生物标志物关系的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/659b/12100503/0a723866d419/ALZ-21-e70291-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/659b/12100503/fcf0ec48a5de/ALZ-21-e70291-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/659b/12100503/0a723866d419/ALZ-21-e70291-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/659b/12100503/fcf0ec48a5de/ALZ-21-e70291-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/659b/12100503/0a723866d419/ALZ-21-e70291-g002.jpg

相似文献

1
A brief history of Aβ imaging.Aβ成像简史。
Alzheimers Dement. 2025 May;21(5):e70291. doi: 10.1002/alz.70291.
2
Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross-sectional associations with early cognitive impairments.唐氏综合征和临床前阿尔茨海默病中β-淀粉样蛋白和tau病理的联合空间关联:与早期认知障碍的横断面关联
Alzheimers Dement. 2025 Jul;21(7):e70424. doi: 10.1002/alz.70424.
3
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing.在澳大利亚衰老成像、生物标志物和生活方式研究中,基线习惯性膳食硝酸盐摄入量与阿尔茨海默病相关神经影像学生物标志物。
J Prev Alzheimers Dis. 2025 Jun;12(6):100161. doi: 10.1016/j.tjpad.2025.100161. Epub 2025 Apr 11.
4
Longitudinal head-to-head comparison of C-PiB and F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.在一项针对显性遗传性阿尔茨海默病的抗淀粉样蛋白β单克隆抗体的 2/3 期临床试验中,进行 C-PiB 和 F-氟比他滨 PET 的纵向对头比较。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2669-2682. doi: 10.1007/s00259-023-06209-0. Epub 2023 Apr 5.
5
A Novel Design of a Portable Birdcage via Meander Line Antenna (MLA) to Lower Beta Amyloid (Aβ) in Alzheimer's Disease.一种通过曲折线天线(MLA)设计的便携式鸟笼,用于降低阿尔茨海默病中的β淀粉样蛋白(Aβ)。
IEEE J Transl Eng Health Med. 2025 Apr 10;13:158-173. doi: 10.1109/JTEHM.2025.3559693. eCollection 2025.
6
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.淀粉样蛋白 PET 和 tau-PET 评估唐氏综合征患者症状性阿尔茨海默病的时间轴:一项纵向队列研究。
Lancet Neurol. 2024 Dec;23(12):1214-1224. doi: 10.1016/S1474-4422(24)00426-5.
7
Co-Aggregation of Syndecan-3 with β-Amyloid Aggravates Neuroinflammation and Cognitive Impairment in 5×FAD Mice.Syndecan-3与β-淀粉样蛋白的共聚集加重5×FAD小鼠的神经炎症和认知障碍。
Int J Mol Sci. 2025 Jun 8;26(12):5502. doi: 10.3390/ijms26125502.
8
Elevated CSF GAP-43 in Mild Cognitive Impairment Linked to Cognitive Impairment Through Increased Amyloid-β Accumulation, with a Shift to Reduced Amyloid-β Accumulation in Alzheimer's Disease.轻度认知障碍患者脑脊液中生长相关蛋白43(GAP-43)升高,通过淀粉样β蛋白(Aβ)积累增加与认知障碍相关,而在阿尔茨海默病中则转变为Aβ积累减少。
J Mol Neurosci. 2025 Mar 20;75(2):39. doi: 10.1007/s12031-025-02333-8.
9
Crystal Violet Selectively Detects Aβ Oligomers but Not Fibrils In Vitro and in Alzheimer's Disease Brain Tissue.结晶紫在体外和阿尔茨海默病脑组织中选择性检测 Aβ 寡聚体而不是纤维。
Biomolecules. 2024 May 23;14(6):615. doi: 10.3390/biom14060615.
10
Parenchymal CSF fraction is a measure of brain glymphatic clearance and positively associated with amyloid beta deposition on PET.脑实质 CSF 分数是脑内糖胶质清除的衡量指标,与 PET 上的淀粉样β沉积呈正相关。
Alzheimers Dement. 2024 Mar;20(3):2047-2057. doi: 10.1002/alz.13659. Epub 2024 Jan 7.

本文引用的文献

1
Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable.关于适用于启动抗淀粉样蛋白治疗的 Centiloid 阈值的专家意见。2024 年春季阿尔茨海默病协会研究圆桌会议讨论总结。
J Prev Alzheimers Dis. 2025 Jan;12(1):100008. doi: 10.1016/j.tjpad.2024.100008. Epub 2025 Jan 1.
2
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.淀粉样蛋白和tau蛋白PET的更新后合理使用标准:阿尔茨海默病协会与核医学和分子影像学会工作组的报告
Alzheimers Dement. 2025 Jan;21(1):e14338. doi: 10.1002/alz.14338. Epub 2025 Jan 8.
3
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.
血浆磷酸化 tau 217 和 Aβ42/40 预测认知正常人群的早期脑 Aβ 蓄积。
JAMA Neurol. 2024 Sep 1;81(9):947-957. doi: 10.1001/jamaneurol.2024.2619.
4
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准:阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
5
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
6
Lecanemab: Appropriate Use Recommendations.仑卡奈单抗:合理使用建议。
J Prev Alzheimers Dis. 2023;10(3):362-377. doi: 10.14283/jpad.2023.30.
7
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
8
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.AHEAD 3-45 研究:阿尔茨海默病预防试验设计。
Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15.
9
The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.淀粉样蛋白 PET 在神经退行性疾病成像中的作用:综述。
J Nucl Med. 2022 Jun;63(Suppl 1):13S-19S. doi: 10.2967/jnumed.121.263195.
10
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.